TRON Group Inc. and Nanopharmaceutics Inc. announced the signing of a definitive agreement for the merger of Nano with NANOP Acquisition Corp. Inc. Following consummation of the Merger, TRON will change its name to Nanopharmaceutics Inc. and will continue to trade on the OTC Pink market. The merger was unanimously approved by both Boards of Directors of TRON and Nano.

Under the terms of the agreement, in an all-stock transaction, Nano and NANOP will merge. TRON will issue five shares of recently authorized and designated Class A Preferred stock to Nano shareholders in exchange for all the issued and outstanding shares of Nano. The Company intends to file a corporate action with FINRA in respect of the aforementioned name change.

James D. Talton, Ph.D., President and Chief Executive Officer and controlling shareholder of both TRON and Nanopharmaceutics, has been appointed James D. Talton, Ph.D., President and Chief Executive Officer and controlling shareholder of both TRON and Nanopharmaceutics, has been appointed Chief Executive Officer, President, Secretary/Treasurer and Director of TRON, effective August 8, 2022.